Eli Lilly And Co vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.16 (market cap $159.33M). The key difference: Eli Lilly And Co is far larger — about 6527.3× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Roundhill Russell 2000 0DTE Covered Call Strat ETF for 54 Days on average.
| LLY | RDTE | |
|---|---|---|
Market Cap | $1.04T | $159.33M |
Volume | 3,064,878 | 248,058 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.28K | $33.66 |
52-Week Low | $799.57 | $25.96 |
Typical Hold Time | 93 Days | 54 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →